Cholecystitis resident survival guide: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 53: | Line 53: | ||
{{familytree | | | | | | | | | |!| |!| | | | | | | | | |!| | | | | | | | | | |}} | {{familytree | | | | | | | | | |!| |!| | | | | | | | | |!| | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | F01 |+| F02 |-| F03 |-| F04 | | | | | | | | | | | | | | |F01='''Order urgent transabdominal USG (TAUSG)'''|F02=GBS w/o GB edema/GB edema w/o GBS|F03=HIDA scan|F04=GB visualized}} | {{familytree | | | | | | | | | F01 |+| F02 |-| F03 |-| F04 | | | | | | | | | | | | | | |F01='''Order urgent transabdominal USG (TAUSG)'''|F02=GBS w/o GB edema/GB edema w/o GBS|F03=HIDA scan|F04=GB visualized}} | ||
{{familytree | | | | | | | | | | | {{familytree | | | | | | | | | | | |!| | | | | |!| | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | | {{familytree | | | | | | | | | | | |`| G01 | | G02 | | | | | | | | | | | | | | | | |G01=GBS w/ GB edema|G02=GB not visualized}} | ||
{{familytree | | | | | | | | | | | {{familytree | | | | | | | | | | | | | |!| | | |!| | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | | | {{familytree | | | | | | | | | | | | | |!| | | |!| | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | H01 |-|-|^|-|-|-|'| | | | | | | | | | | | | | | |H01=<div style="float: left; text-align: left; line-height: 150% ">'''Diagnostic criteria:'''<ref name="Takada-2007">{{Cite journal | last1 = Takada | first1 = T. | last2 = Kawarada | first2 = Y. | last3 = Nimura | first3 = Y. | last4 = Yoshida | first4 = M. | last5 = Mayumi | first5 = T. | last6 = Sekimoto | first6 = M. | last7 = Miura | first7 = F. | last8 = Wada | first8 = K. | last9 = Hirota | first9 = M. | title = Background: Tokyo Guidelines for the management of acute cholangitis and cholecystitis. | journal = J Hepatobiliary Pancreat Surg | volume = 14 | issue = 1 | pages = 1-10 | month = | year = 2007 | doi = 10.1007/s00534-006-1150-0 | PMID = 17252291 }}</ref><ref name="Hirota-2007">{{Cite journal | last1 = Hirota | first1 = M. | last2 = Takada | first2 = T. | last3 = Kawarada | first3 = Y. | last4 = Nimura | first4 = Y. | last5 = Miura | first5 = F. | last6 = Hirata | first6 = K. | last7 = Mayumi | first7 = T. | last8 = Yoshida | first8 = M. | last9 = Strasberg | first9 = S. | title = Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines. | journal = J Hepatobiliary Pancreat Surg | volume = 14 | issue = 1 | pages = 78-82 | month = | year = 2007 | doi = 10.1007/s00534-006-1159-4 | PMID = 17252300 }}</ref><br>❑ Local symptoms & signs<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed"> | {{familytree | | | | | | | | | H01 |-|-|^|-|-|-|'| | | | | | | | | | | | | | | |H01=<div style="float: left; text-align: left; line-height: 150% ">'''Diagnostic criteria:'''<ref name="Takada-2007">{{Cite journal | last1 = Takada | first1 = T. | last2 = Kawarada | first2 = Y. | last3 = Nimura | first3 = Y. | last4 = Yoshida | first4 = M. | last5 = Mayumi | first5 = T. | last6 = Sekimoto | first6 = M. | last7 = Miura | first7 = F. | last8 = Wada | first8 = K. | last9 = Hirota | first9 = M. | title = Background: Tokyo Guidelines for the management of acute cholangitis and cholecystitis. | journal = J Hepatobiliary Pancreat Surg | volume = 14 | issue = 1 | pages = 1-10 | month = | year = 2007 | doi = 10.1007/s00534-006-1150-0 | PMID = 17252291 }}</ref><ref name="Hirota-2007">{{Cite journal | last1 = Hirota | first1 = M. | last2 = Takada | first2 = T. | last3 = Kawarada | first3 = Y. | last4 = Nimura | first4 = Y. | last5 = Miura | first5 = F. | last6 = Hirata | first6 = K. | last7 = Mayumi | first7 = T. | last8 = Yoshida | first8 = M. | last9 = Strasberg | first9 = S. | title = Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines. | journal = J Hepatobiliary Pancreat Surg | volume = 14 | issue = 1 | pages = 78-82 | month = | year = 2007 | doi = 10.1007/s00534-006-1159-4 | PMID = 17252300 }}</ref><br>❑ Local symptoms & signs<div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed"> | ||
:❑ Murphy’s sign | :❑ Murphy’s sign | ||
Line 67: | Line 67: | ||
:❑ HIDA scan confirmatory finding of GBS & GB edema </div></div></div>}} | :❑ HIDA scan confirmatory finding of GBS & GB edema </div></div></div>}} | ||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | I01 | | | | | | | | | | | | | | | | | | | | | | |I01='''Acute calculous cholecystitis'''}} | {{familytree | | | | | | | | | I01 | | | | | | | | | | | | | | | | | | | | | | |I01='''Acute calculous cholecystitis'''<br>w/ or w/o complications}} | ||
{{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}} | {{familytree | | | | | | | | | |!| | | | | | | | | | | | | | | | | | | | | | |}} | ||
{{familytree | | | | | | | | | J01 | | {{familytree | | | | | | | | | J01 | | | | | | | | | | | | | | | | | | | | | | |J01=<div style="float: left; text-align: left; line-height: 150% "><BR>❑ Hospital admission<BR>❑ NPO<br>❑ IVF & correct electrolyte abnormalities<br>❑ Empiric IV antibiotics<ref name="Solomkin-2003">{{Cite journal | last1 = Solomkin | first1 = JS. | last2 = Mazuski | first2 = JE. | last3 = Baron | first3 = EJ. | last4 = Sawyer | first4 = RG. | last5 = Nathens | first5 = AB. | last6 = DiPiro | first6 = JT. | last7 = Buchman | first7 = T. | last8 = Dellinger | first8 = EP. | last9 = Jernigan | first9 = J. | title = Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. | journal = Clin Infect Dis | volume = 37 | issue = 8 | pages = 997-1005 | month = Oct | year = 2003 | doi = 10.1086/378702 | PMID = 14523762 }}</ref><div class="mw-collapsible-content"> <div class="mw-collapsible mw-collapsed"> | ||
:❑ Ceftriaxone 1 g IV every 24 hours or 2 g IV every 12 hours for CNS infections + Metronidazole 500 mg IV every 8 hours | :❑ Ceftriaxone 1 g IV every 24 hours or 2 g IV every 12 hours for CNS infections + Metronidazole 500 mg IV every 8 hours | ||
'''or''' | '''or''' | ||
Line 75: | Line 75: | ||
:❑ Ketorolac 30-60 mg IM/IV single dose | :❑ Ketorolac 30-60 mg IM/IV single dose | ||
:❑ Opioids until cholecystectomy if ketorolac is contraindicated/pain not improving<br> | :❑ Opioids until cholecystectomy if ketorolac is contraindicated/pain not improving<br> | ||
❑ Assess | ❑ [[Cholecystitis overview#Severity Grading|Assess severity]]<ref name="Hirota-2007">{{Cite journal | last1 = Hirota | first1 = M. | last2 = Takada | first2 = T. | last3 = Kawarada | first3 = Y. | last4 = Nimura | first4 = Y. | last5 = Miura | first5 = F. | last6 = Hirata | first6 = K. | last7 = Mayumi | first7 = T. | last8 = Yoshida | first8 = M. | last9 = Strasberg | first9 = S. | title = Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines. | journal = J Hepatobiliary Pancreat Surg | volume = 14 | issue = 1 | pages = 78-82 | month = | year = 2007 | doi = 10.1007/s00534-006-1159-4 | PMID = 17252300 }}</ref></div>}} | ||
{{familytree | | | | | | | | | |)|-|-|-|-|v|-|-|-|-|.| | | | | | | | | | | | | }} | |||
{{familytree | | | | | | | | | K01 | | | K02 | | | K03 | | | | | | | | | | | | | | |K01=Grade 1 (Mild)|K02=Grade 2 (Moderate)|K03=Grade 3 (Severe)}} | |||
{{familytree | | | | | | | | | |!| | | | |!| | | | |!| | | | | | | | | | |}} | |||
{{familytree | | | | | | | | | L01 | | | L02 | | | L03 | | | | | | | | |L01=Laparoscopic cholecystectomy within 72 hours|L02=<div style="float: left; text-align: left; line-height: 150% ">'''W/o complications & non high risk surgical candidates:'''<br>Immediate cholecystectomy + blood C&S ± bile C&S<br>'''W/o complications & high risk surgical candidates:'''<br>Immediate biliary drainage + blood C&S ± bile C&S<br>'''W/ complications:'''<br>Emergency cholecystectomy + blood C&S ± bile C&S ± appropriate surgeries for [[Gallstone ileus#Treatment|gallstone ileus]] & [[Mirizzi's syndrome surgery|Mirizzi syndrome]]</div>|L03=Emergency biliary drainage + blood C&S ± bile C&S}} | |||
{{familytree | | | | | | | | | | | | | | | | | | | |!| | | | | | | | | | |}} | |||
{{familytree | | | | | | | | | | | | | | | | | | | M01 | | | | | | | | | | | |M01=Cholecystectomy after 3 months if GBS found during biliary drainage}} | |||
==References== | ==References== |
Revision as of 19:47, 8 January 2014
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Vendhan Ramanujam M.B.B.S [2]
Cholecystitis
Definitions
Terms | Definitions |
---|---|
Cholecystitis | Cholecystitis is an inflammatory disease of the gallbladder. |
Acute cholecystitis | Acute cholecystitis is an acute inflammatory disease of the gallbladder, most often attributable to gallstones.[1][2] |
Acute calculous cholecystitis | Acute calculous cholecystitis is an acute inflammatory disease of the gallbladder in the presence of cholelithiasis.[1] |
Acute acalculous cholecystitis | Acute acalculous cholecystitis is an acute necroinflammatory disease of the gallbladder in the absence of cholelithiasis and has a multifactorial pathogenesis.[3] |
Chronic cholecystitis | Chronic cholecystitis is a chronic inflammatory disease of the gallbladder with histological evidence of chronic inflammation like large range of related inflammatory epithelial changes including mononuclear infiltrate, fibrosis, thickening of muscular layer, dysplasia, hyperplasia and metaplasia.[4] |
Acute Calculous Cholecystitis Diagnostic Criteria
The Tokyo guidelines is used in the diagnosis of acute calculous cholecystitis.[5][6]
Causes
Life Threatening Causes
Life-threatening causes include conditions which may result in death or permanent disability within 24 hours if left untreated.
Common Causes
Management
References
- ↑ 1.0 1.1 Strasberg, SM. (2008). "Clinical practice. Acute calculous cholecystitis". N Engl J Med. 358 (26): 2804–11. doi:10.1056/NEJMcp0800929. PMID 18579815. Unknown parameter
|month=
ignored (help) - ↑ Reiss, R.; Deutsch, AA. (1993). "State of the art in the diagnosis and management of acute cholecystitis". Dig Dis. 11 (1): 55–64. PMID 8443956.
- ↑ Huffman, JL.; Schenker, S. (2010). "Acute acalculous cholecystitis: a review". Clin Gastroenterol Hepatol. 8 (1): 15–22. doi:10.1016/j.cgh.2009.08.034. PMID 19747982. Unknown parameter
|month=
ignored (help) - ↑ Zhou, D.; Guan, WB.; Wang, JD.; Zhang, Y.; Gong, W.; Quan, ZW. (2013). "A comparative study of clinicopathological features between chronic cholecystitis patients with and without Helicobacter pylori infection in gallbladder mucosa". PLoS One. 8 (7): e70265. doi:10.1371/journal.pone.0070265. PMID 23936177.
- ↑ 5.0 5.1 Takada, T.; Kawarada, Y.; Nimura, Y.; Yoshida, M.; Mayumi, T.; Sekimoto, M.; Miura, F.; Wada, K.; Hirota, M. (2007). "Background: Tokyo Guidelines for the management of acute cholangitis and cholecystitis". J Hepatobiliary Pancreat Surg. 14 (1): 1–10. doi:10.1007/s00534-006-1150-0. PMID 17252291.
- ↑ 6.0 6.1 6.2 Hirota, M.; Takada, T.; Kawarada, Y.; Nimura, Y.; Miura, F.; Hirata, K.; Mayumi, T.; Yoshida, M.; Strasberg, S. (2007). "Diagnostic criteria and severity assessment of acute cholecystitis: Tokyo Guidelines". J Hepatobiliary Pancreat Surg. 14 (1): 78–82. doi:10.1007/s00534-006-1159-4. PMID 17252300.
- ↑ Solomkin, JS.; Mazuski, JE.; Baron, EJ.; Sawyer, RG.; Nathens, AB.; DiPiro, JT.; Buchman, T.; Dellinger, EP.; Jernigan, J. (2003). "Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections". Clin Infect Dis. 37 (8): 997–1005. doi:10.1086/378702. PMID 14523762. Unknown parameter
|month=
ignored (help)
Characterize the symptoms ❑ Abdominal pain | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Acute biliary type abdominal pain
❑ Sx suggestive of sepsis ❑ Sx suggestive of Mirizzi syndrome ❑ Sx suggestive of gallstone ileus | ❑ Acute vague abdominal pain ❑ RUQ mass ❑ Jaundice | ❑ Recurrent biliary type abdominal pain ❑ Recurrent abdominal bloating ❑ Unstable stool with constipation/diarrhea | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Examine the patient: ❑ Febrile ❑ Tachycardia ❑ Dehydrated ❑ Abdominal guarding ❑ Murphy's sign ❑ Abdominal creps ❑ Abdominal tenderness ❑ Reduced bowel sounds ❑ Increased bowel sounds ❑ Abdominal distension ❑ Signs of sepsis | Consider Dx of acute acalculous cholecystitis | Consider Dx of chronic cholecystitis | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Order laboratory tests: ❑ CBC ❑ BMP ❑ Total bilirubin ❑ Direct bilirubin ❑ Albumin ❑ AST ❑ ALT ❑ Alkaline phosphatase ❑ GGT ❑ Amylase ❑ Lipase | No GBS/GB edema | Consider evaluation for alternate diagnosis of abdominal pain | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Order urgent transabdominal USG (TAUSG) | GBS w/o GB edema/GB edema w/o GBS | HIDA scan | GB visualized | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
GBS w/ GB edema | GB not visualized | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Acute calculous cholecystitis w/ or w/o complications | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
❑ Hospital admission ❑ NPO ❑ IVF & correct electrolyte abnormalities ❑ Empiric IV antibiotics[7]
or
❑ Acute pain management | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Grade 1 (Mild) | Grade 2 (Moderate) | Grade 3 (Severe) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Laparoscopic cholecystectomy within 72 hours | W/o complications & non high risk surgical candidates: Immediate cholecystectomy + blood C&S ± bile C&S W/o complications & high risk surgical candidates: Immediate biliary drainage + blood C&S ± bile C&S W/ complications: Emergency cholecystectomy + blood C&S ± bile C&S ± appropriate surgeries for gallstone ileus & Mirizzi syndrome | Emergency biliary drainage + blood C&S ± bile C&S | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Cholecystectomy after 3 months if GBS found during biliary drainage | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||